Overview

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Investigate the use of BYL719 (alpelisib) as combination therapy with Nab-Paclitaxel in locally recurrent or metastatic HER-2 negative breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Priyanka Sharma
University of Kansas Medical Center
Collaborator:
Novartis Pharmaceuticals
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Taxane